Adds company comments in bullet 2, 3 and 9, analyst comment in bullet 4, shares in bullet 9

By Siddhi Mahatole

May 5 (Reuters) - Revvity RVTY.N on Tuesday lowered its annual profit and revenue forecast, as the medical equipment maker excludes its immunodiagnostics business in China that it plans to divest.

Here are the results:

• The company said it has decided to sell its immunodiagnostics business in China, which accounted for about 6% of its total revenue in the 2025 fiscal year.

• "The healthcare market in China, particularly diagnostics, has faced persistent policy-induced headwinds that have dramatically impacted both customer demand and pricing dynamics," CEO Prahlad Singh said.

• "Unfortunately, we see these challenges continuing over the medium term."

• Revvity has signed a letter of intent with a potential buyer and expects to reach a definitive agreement in the second quarter of 2026, with the transaction targeted to close in 2027, subject to regulatory approvals, the company said.

• "We see the China IMDx divestiture as the right decision strategically and should aid organic growth by ~100 basis points," Evercore ISI analyst Vijay Kumar said.

• Revvity lowered its annual forecast for adjusted profit to be between $5.20 and $5.30 per share from the previous view of $5.35 to $5.45. Analysts were expecting annual profit of $5.39 per share, according to data compiled by LSEG.

• It expects annual sales in the range of $2.81 billion to $2.84 billion, compared with the prior range of $2.96 billion to $2.99 billion.

• Life-sciences tools and services companies have been contending with cautious post-pandemic funding for smaller biotechs and weak academic research funding.

• In the U.S., the company saw positive growth from pharma biotech and academic customers for the first time since the second quarter of 2023, Singh said.

• Shares of the company rose 4% premarket after it earned quarterly adjusted profit of $1.06 per share, beating estimates of $1.02.